Winst gevend schreef op 5 juli 2021 06:44:
AbiVax’s Partnering Prospects For MicroRNA-based Drug Boosted By Rheumatoid Arthritis Data
Phase IIa RA Results Build On Ulcerative Colitis Promise
23 Jun 2021
Now that AbiVax's novel anti-inflammatory ABX464 has demonstrated solid safety and efficacy
in rheumatoid arthritis and ulcerative colitis, the French biotech is exploring additional programs
in chronic inflammatory indications – and looking for a partner.
Zou kunnen passen..............